John P. Schmid
CIK 1478916 · Chief Financial Officer · last filed 2026-06-11
John P. Schmid is a Chief Financial Officer who has filed 79 SEC Form 4 insider transactions across 9 companies since 2010. The most recent filing, for DSGN, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.37M
9
79
-$1.09M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DSGN | Director | 57,639 | $10.97 | $632.3K | $99.7K | 7 | 2026-06-11 |
| TRAX | Director | 31,622 | — | — | $0 | 2 | 2026-05-14 |
| ANAB | Director | 32,144 | $56.07 | $1.80M | -$1.16M | 17 | 2026-04-22 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 7 | 2025-01-08 |
| XERS | Director | 138,359 | $6.79 | $939.5K | $50.1K | 12 | 2024-08-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 6 | 2021-03-19 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Financial Officer | 0 | — | — | $0 | 2 | 2015-05-06 |
| Trius Therapeutics Inc (TSRX) Delisted | Chief Financial Officer | 107,639 | — | — | -$85.0K | 23 | 2013-03-11 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2026-05-14 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-04-22 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-04-22 | ANAB | Mixed | — | $0 | EDGAR |
| 2026-04-01 | ANAB | Sell (S) | −20,645 | -$1.16M | EDGAR |
| 2026-01-08 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2025-12-23 | ANAB | Other (J) | −11,068 | -$564.5K | EDGAR |
| 2025-08-11 | BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | Exer (M) | +30,000 | $0 | EDGAR |
| 2025-06-17 | ANAB | Exer (M) | +6,030 | $0 | EDGAR |
| 2025-06-12 | DSGN | Grant (A) | — | $0 | EDGAR |